P3 Health Partners Inc. - PIII STOCK NEWS

P3 Health Partners (NASDAQ: PIII) announced its financial results for Q3 2024, ending September 30, 2024. Revenue increased by 26% YoY to $362.1 million. Capitated revenue rose by 25% to $357.7 million. However, the company reported a gross profit loss of $39.8 million, compared to a gross profit of $9.1 million in the previous year. The medical margin was $0.5 million, down from $36.2 million last year. Net loss widened to $102.9 million, up from $37.3 million. Adjusted EBITDA loss was $71.0 million, compared to $22.3 million in Q3 2023. Due to lower-than-expected risk adjustments and elevated medical costs, the company is withdrawing its previous FY 2024 guidance. Management will host a conference call on November 12, 2024, at 4:30 PM ET to discuss these results.

P3 Health Partners (NASDAQ: PIII), a patient-centered and physician-led population health management company, has announced its upcoming third quarter 2024 financial results release and conference call. The company will release its Q3 2024 results and file its Quarterly Report on Form 10-Q on Tuesday, November 12, 2024. Management will host a conference call at 4:30 PM ET the same day to discuss the results. The call will be accessible via toll-free number 1-833-316-0546 (US) or international number 1-412-317-0692, and will also be webcast live on the company's investor website.

P3 Health Partners Inc. (NASDAQ: PIII), a patient-centered and physician-led population health management company, has announced its participation in the LD Micro Main Event XVII Conference. The event is scheduled for Wednesday, October 30, 2024, in Los Angeles, CA.

The company's management team will deliver a presentation at 2:30 pm Eastern Time. Interested parties can access a live webcast of the presentation through P3's Investor Relations Website at https://ir.p3hp.org/.

This conference appearance provides an opportunity for P3 Health Partners to showcase its business model and strategies to potential investors and industry professionals.

P3 Health Partners (NASDAQ: PIII) has announced the appointment of Leif Pedersen as its new Chief Financial Officer, effective October 1, 2024. Pedersen, with over 25 years of experience in finance and value-based care, will succeed Atul Kavthekar, who will transition to a Strategic Advisor role. Pedersen's background includes serving as VP of Finance & CFO Shared Services at Optum Health and VP of Finance & CFO IT at DaVita Medical Group.

In his new role, Pedersen will oversee Accounting, Treasury, Finance Analytics, and Investor Relations. P3's CEO, Dr. Aric Coffman, expressed confidence in Pedersen's ability to help the company achieve its long-term goals while maintaining excellence in value-based care.

P3 Health Partners (NASDAQ: PIII), a patient-centered and physician-led population health management company, has announced its participation in two upcoming investor conferences. The company will be present at:

• The 2024 Wells Fargo Healthcare Conference in Boston, MA on Wednesday, September 4, 2024
• The Lake Street Best Ideas Growth Conference in New York, NY on Thursday, September 12, 2024

These conferences provide P3 Health Partners with opportunities to showcase their business model and growth strategies to potential investors and industry analysts. The company's presence at these events underscores its commitment to engaging with the investment community and highlighting its role in the evolving healthcare landscape.

P3 Health Partners (NASDAQ: PIII) released its financial results for Q2 2024, ending June 30. The company reported total revenue of $379.2 million, marking a 15% increase from $329.1 million in Q2 2023. Capitated revenue also saw a 15% rise to $374.3 million. However, gross profit declined to $14 million from $26.8 million last year, and profit per member per month (PMPM) dropped to $36 from $86. The medical margin decreased to $41.1 million from $50.5 million, while net loss widened to $28.8 million compared to $27.6 million. Adjusted EBITDA showed a loss of $8.8 million vs. a gain of $0.2 million last year. For fiscal 2024, P3 projects total revenue between $1.45 billion and $1.55 billion, a medical margin of $230-250 million, and adjusted EBITDA between $20-40 million.

P3 Health Partners Inc. (NASDAQ: PIII), a patient-centered and physician-led population health management company, has announced its plans to release second quarter 2024 financial results and file its Quarterly Report on Form 10-Q on Wednesday, August 7, 2024. The company will host a conference call to discuss the financial results at 1:30pm PT/ 4:30pm ET on the same day.

Investors can join the conference call via toll-free number 1-833-316-0546 (US) or international number 1-412-317-0692. The call will also be webcast live in the 'Events & Presentations' section of P3's Investor page. An archived recording of the webcast will be available on the company's website for 90 days following the conference call.

P3 Health Partners (NASDAQ: PIII), a leader in population health management, announced a strategic partnership with Innovaccer, a prominent healthcare AI company.

This collaboration aims to advance value-based care by leveraging Innovaccer's Healthcare AI Platform to improve patient outcomes, optimize costs, and enhance the patient and clinician experience. The platform will help P3 Health Partners unify, aggregate, and normalize clinical and claims data, reducing administrative tasks, improving data integration, and enhancing analytics for better care management.

P3 will utilize Innovaccer's EHR-agnostic physician engagement solution, population health analytics suite, and patient engagement solution to close care gaps and drive better patient engagement across its regions.

P3 Health Partners (NASDAQ: PIII), a population health management company, announced its participation in upcoming investor conferences. These include the William Blair 44th Annual Growth Stock Conference in Chicago, IL on June 4, 2024, where P3 will present at 12:20 pm Eastern Time, and the Jefferies Healthcare Conference in Miami Beach, FL on June 6, 2024, with a presentation at 11:00 am Eastern Time.

Both presentations will be webcast live on P3's investor relations website, with replays available for 90 days following the events.